Dymista (azelastine + fluticasone)
Dymista nasal spray contains antihistamine (azelastine) and glucocorticoid (fluticasone). It is indicated for the treatment of moderate to severe allergic rhinitis. Based on the “total nasal score system” Dymista showed a significantly better effect compared to placebo as well as the drug substances separately. IRF do not, in general, recommend combining drug treatments. It is IRF’s overall assessment that Dymista is an option in cases where a satisfactory response is not achieved with currently available glucocorticoids for nasal use.
The nasal spray is approved for adults and children above the age of 12. Dymista is currently more expensive than nasal sprays containing only glucocorticoids.
Dymista was marketed on March 18th 2013 and is subject to general reimbursement.